We urge the USPSTF to consider the following two recommendations as it finalizes its plan “Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis”: research should explicitly evaluate and describe the ancillary services that are integral to the PrEP intervention and the USPSTF should adopt a more nimble and timely review of the PrEP recommendation as new products see clinical trial success.
PrEP is a critical component to ending the HIV epidemic; however, its uptake has been limited, particularly in communities most at risk of HIV, including Black and Latino gay men and Black women. While there are established government programs that are funded for the treatment of HIV, there is no comprehensive nationwide program dedicated for the provision of PrEP. The “PrEP Assistance Program Act” would help fill that void by providing grants to states, community-based organizations, community health centers, and others to establish and support PrEP programs.
CDC responds to HIV community request led by HIV+Hep to allow HIV prevention funds for PrEP ancillary services
We know that access to quality PrEP care is critical to HIV prevention efforts and we will continue to work with our partners to look for ways to expand PrEP services and commit to equitably expanding access to and uptake of PrEP. As part of Ending the HIV Epidemic in the U.S., state and local communities (in partnership with CDC and other federal agencies) are employing innovative strategies, such as telePrEP and same-day PrEP delivery, to increase access to and use of PrEP. These efforts focus on African American and Latino gay and bisexual men, African American women, and other populations disproportionately affected by HIV. We appreciate the input from you and your co-signatories and our partnership in HIV prevention.
We, the undersigned 46 organizations, on behalf of millions of American patients who live with complex, chronic health conditions such as HIV, autoimmune diseases, cancer, diabetes, lupus, multiple sclerosis, and hepatitis, are pleased that your committee and Congress are focused on advancing policies and measures that improve prescription drug affordability and access for the American people. We believe there are clear actions that Congress can take right now to help patients access, afford, and adhere to the medications they need to stay healthy. However, several proposals on the table would create great challenges for those we serve and have negative implications for vulnerable communities and future treatment innovations.
HIV+Hep & 62 organizations send a letter to USPSTF requesting an update of PrEP recommendations to include long-acting agents.